1.      Oral semaglutide 25 mg once daily reduced body weight by 14% vs 2% with placebo at 64 weeks in the OASIS-4 trial.

2.      Patients on semaglutide showed improvements in body-mass index, waist circumference, glycated hemoglobin, fasting glucose, triglycerides, insulin, and C-reactive protein.

3.      More than half of patients on semaglutide reported clinically meaningful improvements on the IWQOL-Lite-CT Physical Function scale.

4.      Gastrointestinal events were most common (74% semaglutide vs 42% placebo), typically mild to moderate. No deaths occurred.

5.      The trial had more female patients, smaller subgroup sizes, about 20% non-completion, and no active comparator such as higher oral or injectable semaglutide.

Source: NEJM